Clinical study on the incidence of side effects of different doses of Kanglaite capsule in postoperative adjuvant application of early non-small cell lung cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200058310

Enrollment

Unknown

Registered

2022-04-05

Start date

2022-05-01

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Case series:Kanglaite capsule

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with histologically proven early lung cancer after surgery; 2. Aged 18-65 years; 3. Expected follow-up time >=12 months; 4. Patients with normal heart function, liver and kidney function volunteered to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Patients with contraindications in the use of drugs in this study; 2. Patients with drug allergy; 3. Patients with severe abnormal lipid metabolism; 4. Pregnant and lactating patients; 5. Poor follow-up compliance; 6. Did not follow the prescribed medication method; 7. No other malignant tumors were present.

Design outcomes

Primary

Measure	Time frame
Adverse Event;	—

Countries

China

Contacts

Public ContactHu Jian

2854943026@qq.com+86 17816858920

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026